This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mitochondrial disorders may be associated with symptomatic myoclonus. Myoclonus is a cardinal feature of the progressive myoclonus epilepsy syndromes (PMEs), recognized causes of which are the mitochondrial disorders myoclonic epilepsy with ragged red fibers (MERRF) and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). MELAS presents with normal early development, stroke-like episodes at a young age, encephalopathy, epilepsy, cognitive decline, lactic acidosis, and ragged-red fibers on skeletal muscle biopsy. Myoclonus and partial seizures are common but variable clinical features.1 Presently, the treatment of myoclonus and epilepsy in the setting of MELAS and MERRF and other nonsyndromic mitochondrial disorders is empiric and largely based on anecdotal experience. There are no published reports on the use of lamotrigine in these mitochondrial disorders. The mechanism of action of lamotrigine is incompletely understood but, in part, is thought to interact with voltage-gated sodium channels leading to modification of ion fluxes. In this report, we describe the enduring abolition of disabling myoclonus in a patient …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.